Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control

被引:81
|
作者
Ting, F. [1 ,2 ,3 ]
Tran, M. [1 ,2 ,3 ]
Boehm, M. [2 ]
Siriwardana, A. [1 ,2 ,3 ]
Van Leeuwen, P. J. [1 ,2 ]
Haynes, A-M [2 ]
Delprado, W. [4 ]
Shnier, R. [5 ]
Stricker, P. D. [1 ,2 ,3 ]
机构
[1] St Vincents Prostate Canc Ctr, Darlinghurst, NSW, Australia
[2] Kinghorn Canc Ctr, Garvan Inst Med Res, Darlinghurst, NSW, Australia
[3] Univ New S Wales, Sch Med, Sydney, NSW, Australia
[4] Douglass Hanly Moir Pathol, Macquarie Pk, NSW, Australia
[5] Southern Radiol, Randwick, NSW, Australia
基金
英国医学研究理事会;
关键词
ABLATION; THERAPY; METAANALYSIS; TRIAL; MEN;
D O I
10.1038/pcan.2015.47
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Current data on the use of irreversible electroporation (IRE) in the treatment of prostate cancer (PCa) is limited. We aim to evaluate the safety, short-term functional and oncological outcomes of focal IRE in low-intermediate risk PCa. METHODS: Between February 2013 and May 2014, 32 consecutive men underwent IRE at a single centre. Patients with low-intermediate risk PCa who had not received previous PCa treatment were included for analysis. The tumour was ablated using 3-6 electrodes, ensuring a minimum 5-mm safety margin around the visible magnetic resonance imaging (MRI) lesion. Follow-up included recording Clavien complications, Expanded Prostate Cancer Index Composite (EPIC) questionnaires (baseline, 1.5, 3, 6 months), 6-month multi-parametric MRI (mp-MRI) and 7-month biopsy. Findings on mp-MRI and biopsy were sub-divided into infield, adjacent or outfield of the treatment zone. RESULTS: Twenty-five men were included for final analysis. Safety follow-up revealed one Clavien Grade 3 complication and five Grade 1 complications. Functional follow-up confirmed no significant change in American Urological Association urinary symptom score, sexual or bowel function. Infield, there were no suspicious findings on mp-MRI (n = 24) or biopsy (n = 21) in all patients. Adjacent to the treatment zone, five (21%) had suspicious findings on mp-MRI with four (19%) proving to be significant on biopsy. Outfield, there were two (8%) with suspicious findings on mp-MRI and one (5%) significant finding on biopsy. For the five patients with significant findings on follow-up biopsy, one is awaiting repeat IRE, one had radical prostatectomy and three remained on active surveillance. CONCLUSIONS: In selected patients with low-intermediate risk PCa, focal IRE appears to be safe with minimal morbidity. There were no infield recurrences and 76% of patients were histologically free of significant cancer at 8 months. Almost all recurrences were adjacent to the treatment zone, and this was addressed by widening the treatment margins.
引用
收藏
页码:46 / 52
页数:7
相关论文
共 50 条
  • [21] Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer
    Scheltema, Matthijs J.
    Geboers, Bart
    Blazevski, Alexandar
    Doan, Paul
    Katelaris, Athos
    Agrawal, Shikha
    Barreto, Daniela
    Shnier, Ron
    Delprado, Warick
    Thompson, James E.
    Stricker, Phillip D.
    BJU INTERNATIONAL, 2023, 131 : 6 - 13
  • [22] Focal therapy of index lesion with irreversible electroporation: Oncological and functional results at 30 months
    Lopez B, Minana
    Boville G, De Andres
    Bernardos G, Barbas
    Auba F, Villacampa
    Chillon F, Ramon De Fata
    EUROPEAN UROLOGY, 2022, 81 : S500 - S501
  • [23] Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes
    Blazevski, Alexandar
    Gondoputro, William
    Scheltema, Matthijs J.
    Amin, Amer
    Geboers, Bart
    Barreto, Daniela
    Haynes, Anne-Maree
    Shnier, Ron
    Delprado, Warick
    Agrawal, Shikha
    Thompson, James E.
    Stricker, Phillip D.
    BMC UROLOGY, 2022, 22 (01)
  • [24] Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes
    Collettini, Federico
    Enders, Judith
    Stephan, Carsten
    Fischer, Thomas
    Baur, Alexander D. J.
    Penzkofer, Tobias
    Busch, Jonas
    Hamm, Bernd
    Gebauer, Bernhard
    RADIOLOGY, 2019, 292 (01) : 250 - 257
  • [25] Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes
    Alexandar Blazevski
    William Gondoputro
    Matthijs J. Scheltema
    Amer Amin
    Bart Geboers
    Daniela Barreto
    Anne-Maree Haynes
    Ron Shnier
    Warick Delprado
    Shikha Agrawal
    James E. Thompson
    Phillip D. Stricker
    BMC Urology, 22
  • [26] Using Irreversible Electroporation: Prospective Evaluation of Feasibility, Morbidity, Functional and Oncological Outcomes
    Popeneciu, Ionel Valentin
    Mohr, Mirjam Naomi
    Strauss, Arne
    Leitsmann, Conrad
    Trojan, Lutz
    Reichert, Mathias
    WORLD JOURNAL OF MENS HEALTH, 2024, 42 (04): : 821 - 829
  • [27] FUNCTIONAL AND SHORT-TERM ONCOLOGICAL OUTCOMES WITH ROBOTIC ASSISTED RADICAL PROSTATECTOMY (RARP) IN PREOPERATIVELY HIGH RISK PROSTATE CANCER PATIENTS
    Sivaraman, Ananthakrishnan
    Chauhan, Sanket
    Coelho, Rafael
    Giedelman, Camilo
    Schatloff, Oscar
    Ko, Young Hwii
    Palmer, Kenneth
    Patel, Vipul R.
    Muhsin, Haidar Abdul
    JOURNAL OF ENDOUROLOGY, 2012, 26 : A78 - A79
  • [28] Prostate Carcinoma: Focal Laser Ablation shows good oncological Short-term Data
    von Hardenberg, Jost
    AKTUELLE UROLOGIE, 2017, 48 (04) : 276 - 277
  • [29] Irreversible electroporation as a focal therapy for localized prostate cancer: A systematic review
    Prabhakar, Pushan
    Avudaiappan, Arjun Pon
    Sandman, Mayer
    Eldefrawy, Ahmed
    Caso, Jorge
    Narayanan, Govindarajan
    Manoharan, Murugesan
    INDIAN JOURNAL OF UROLOGY, 2024, 40 (01) : 6 - 16
  • [30] AN UPDATED REVIEW OF PROSTATE CANCER FOCAL THERAPY ONCOLOGICAL, FUNCTIONAL, AND URINARY OUTCOMES
    Marciano, Orry Matthew
    Jung, David
    Pathuri, Manish
    Ikedionwu, Ifeoma
    Raheem, Omer
    JOURNAL OF UROLOGY, 2024, 211 (05): : E861 - E861